SOURCE: Callisto Pharmaceuticals, Inc.

July 07, 2005 13:43 ET

Callisto Pharmaceuticals Appoints Dr. Riccardo Dalla-Favera to Board of Directors

NEW YORK, NY -- (MARKET WIRE) -- July 7, 2005 -- Callisto Pharmaceuticals, Inc. (AMEX: KAL), a biopharmaceutical company primarily focused on the development of drugs to treat cancer, today announced the appointment of Dr. Riccardo Dalla-Favera to its board of directors.

"We are pleased to have Dr. Dalla-Favera join our board," said Dr. Gary S. Jacob, Callisto's Chief Executive Officer. "Dr. Dalla-Favera's depth of experience in the field of hematology and cancer will be an invaluable resource for Callisto as we move forward this year with the clinical trials of our two drugs, Annamycin for relapsed leukemia, and Atiprimod for relapsed multiple myeloma."

"I look forward to the opportunity to work closely with the management team and board of directors as the company embarks on a considerable clinical program in hematology this year," said Dr. Dalla-Favera. "My life's work has been centered on a greater understanding of hematological cancers, and I am pleased to be associated with a company that is pursuing the development of new therapies to treat conditions such as relapsed leukemia and multiple myeloma."

About Dr. Riccardo Dala-Favera

Dr. Dalla-Favera is Director of the Herbert Irving Comprehensive Cancer Center at Columbia University, and the Percy and Joanne Uris Professor of Pathology and Professor of Genetics & Development. Dr. Dalla-Favera is an expert in the field of hematology malignancies, having received his medical degree and completed his training in hematology/oncology at the University of Milan, Italy. After a residency in hematology at the University of Milan and a visiting fellowship at the National Cancer Institute, Dr. Dalla-Favera spent seven years on the New York University School of Medicine faculty, before joining Columbia's College of Physicians and Surgeons in the Department of Pathology, where he presently heads the University's Cancer Center and is the Director of the Specialized Center for Research on Lymphoma at Columbia funded by the Leukemia Lymphoma Society. Dr. Dalla-Favera is a distinguished investigator in the molecular genetics of cancer who has been recognized with several national awards, including the Stohlman Award from The Leukemia Society of America, and two NIH MERIT Awards, and he is an American Association of Physicians Fellow. Dr. Dalla-Favera is on the editorial board of a number of scientific journals, and has authored over 250 papers in peer-reviewed scientific journals.

About Callisto Pharmaceuticals, Inc.

Callisto is a biopharmaceutical company focused on the development of drugs to treat cancer. Callisto has two lead drugs in clinical development, Annamycin to treat relapsed leukemia, and Atiprimod to treat relapsed multiple myeloma. Callisto intends to initiate a clinical trial of Annamycin in relapsed acute lymphoblastic leukemia patients in mid 2005. Annamycin, a drug from the anthracycline family, has a novel therapeutic profile, including activity against resistant diseases and significantly reduced cardiotoxicity. Callisto's second drug, Atiprimod, is in a Phase I/IIa clinical trial in relapsed multiple myeloma patients, and is a small-molecule, orally available drug with antiproliferative and antiangiogenic activity. Callisto also has drugs in preclinical development for melanoma, gastrointestinal inflammation, and a program focused on the development of a drug to protect against staphylococcus and streptococcus biowarfare agents. Callisto has exclusive worldwide licenses from AnorMED Inc. and M.D. Anderson Cancer Center to develop, manufacture, use and sell Atiprimod and Annamycin, respectively. For additional information, visit www.callistopharma.com.

Forward-Looking Statements

Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Callisto believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the Callisto Pharmaceuticals Annual Report on Form 10-K/A for the year ended December 31, 2004,and other periodic reports, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that products that appeared promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the risk that Callisto will not obtain approval to market its products, the risks associated with dependence upon key personnel and the need for additional financing.

Contact Information

  • Investor Relations:
    Marty Tullio or Mark Tullio
    McCloud Communications, LLC
    949.553.9748
    Email Contact
    Email Contact

    Company Contact:
    Dan D'Agostino
    Callisto Pharmaceuticals, Inc.
    212.297.0010 x227
    Email Contact